DGX - Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease
Quest Diagnostics receives New York State approval for Haystack MRD, broadening patient access to ctDNA minimal residual disease testing
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.